Skip to main content

Table 1 Characteristics of the included studies

From: Effect of bisphosphonates on periprosthetic bone loss after total knee arthroplasty: a meta-analysis of randomized controlled trials

Study Age (years), I/C Sample Size, I/C Intervention Follow-up (month) Outcome Measures
Soininvaara 2002 83.5 ± 19.9/ 79.7 ± 8.7 19 (8/11) 10 mg/day oral alendronate+ 500 mg/day calcium carbonate for 12 months vs. 500 mg/day calcium carbonate 12 months Periprosthetic BMD: proximal femur
Han 2003 63.6 ± 4.1/ 65.2 ± 5.6 72 (36/36) 10 mg/day oral alendronate for 6 months vs. no placebo 12 months Periprosthetic BMD: distal part of femur and proximal aspect of tibia
Wang 2006 69.8 ± 5.9/ 69.7 ± 6.7 60 (30/30) 10 mg/day oral alendronate for 6 months vs. no placebo 3 years Periprosthetic BMD:distal part of femur and proximal aspect of tibia
Abu-Rajab 2009 68 ± 2.2/ 72 ± 8.1 11 (5/6) 70 mg/week oral alendronate for 6 months vs. a placebo 2 years Periprosthetic BMD: distal part of femur and proximal aspect of tibia
Jaroma 2015 66 ± 7.0/ 68 ± 8.2 26 (14/12) 10 mg/day oral alendronate+ 500 mg/day calcium carbonate for 12 months vs. 500 mg/day calcium carbonate 7 years Periprosthetic BMD: distal part of femur and proximal aspect of tibia
  1. I/C intervention/control groups, BMD bone mineral density